Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors

HDI afatinib was feasible and tolerable and could potentially be further explored for NSCLC indications, including patients with central nervous system disease, rare EGFR mutations, or T790M+ NSCLC intolerant of third-generation EGFR tyrosine kinase inhibitors.